AR-C68397AA. AstraZeneca.
AR-C68397AA is a dual dopamine D(2)-receptor and beta(2)-adrenoceptor agonist and bronchodilator under development by AstraZeneca (formerly Astra) and undergoing phase I trials for asthma and phase II trials for chronic obstructive pulmonary disease (COPD). AstraZeneca expects to file for drug registration in 2004. Marketing of AR-C68397AA in the US will be assigned to the AstraZeneca/Merck joint marketing venture.
Zacour
M
M
Meakins Christie Laboratories, McGill University, 3626 St Urbain Street, Montreal, H2X 2P2, Canada. mary@meakins.LAN.mcgill.ca